Quantum-Si Presents its Vision to Transform Genomics and Proteomics Research at ASHG 2023
31 Outubro 2023 - 9:00AM
Business Wire
Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or
the “Company”), The Protein Sequencing Company™, today announced it
will showcase next-generation benchtop protein sequencing
instrument, Platinum™, and the Company’s vision to transform
genomics and proteomics research, at the American Society of Human
Genetics (ASHG) conference, in Washington, D.C., November 1-5.
"Platinum, stands as a groundbreaking advancement in
next-generation protein sequencing™ moving the field beyond the
limitations posed by mass spectrometry and immunoassays. This
robust tool is a solution, enabling precise, single-molecule
resolution," remarked Quantum-Si Chief Executive Officer Jeff
Hawkins. He continued, "Platinum is crucial in taking genomic
datasets to the next level, enabling subsequent analysis of
proteins that can unveil genome-to-proteome links that help to
predict phenotype. Platinum will become an essential multi-omics
research tool that is missing in today’s workflows."
Quantum-Si will showcase Platinum’s capabilities at Booth #115,
where Chief Commercial Officer Grace Johnston, Ph.D., and Jeff
Hawkins will be available to discuss the technology and the vital
significance of next-generation protein sequencing and
proteomics.
Additionally, on Thursday, November 2, at 4:30 p.m., Quantum-Si
scientists will present: Unleashing Next-generation Protein
Sequencing™ with Platinum™: How it will Transform Genomics and
Proteomics Research. They will evaluate the challenges associated
with existing proteomics technologies and how Platinum overcomes
them.
Platinum is the world’s first next-generation single-molecule
protein sequencing platform that uses proprietary recognizers to
identify proteins and amino acids using kinetic binding signatures.
Its elegant design and simple workflow enable broad-scale access to
proteomic data, for every scientist, everywhere, making it a
groundbreaking platform for the future of proteomics research. With
its small benchtop design and low price-point, Platinum is poised
to accelerate breakthroughs across scientific disciplines, from
drug discovery to biotech, and help people live healthier and
longer lives.
About Quantum-Si Inc.
Quantum-Si, The Protein Sequencing Company™, is focused on
revolutionizing the growing field of proteomics. The Company's
suite of technologies is powered by a first-of-its-kind
semiconductor chip designed to enable next-generation
single-molecule protein sequencing and digitize proteomic research
in order to advance drug discovery and diagnostics beyond what has
been possible with DNA sequencing. Learn more at
quantum-si.com.
Forward Looking Statements This press release includes
"forward-looking statements" within the meaning of the "safe
harbor" provisions of the United States Private Securities
Litigation Reform Act of 1995. The actual results of the Company
may differ from its expectations, estimates, and projections and,
consequently, you should not rely on these forward-looking
statements as predictions of future events. Words such as "expect,"
"estimate," "project," "budget," "forecast," "anticipate,"
"intend," "plan," "may," "will," "could," "should," "believes,"
"predicts," "potential," "continue," and similar expressions (or
the negative versions of such words or expressions) are intended to
identify such forward-looking statements. These forward-looking
statements include, without limitation, the Company's expectations
with respect to future performance and development and
commercialization of products and services. These forward-looking
statements involve significant risks and uncertainties that could
cause the actual results to differ materially from those discussed
in the forward-looking statements. Most of these factors are
outside the Company's control and are difficult to predict. Factors
that may cause such differences include, but are not limited to:
the impact of COVID-19 on the Company's business; the inability to
maintain the listing of the Company's Class A common stock on The
Nasdaq Stock Market; the ability to recognize the anticipated
benefits of the business combination, which may be affected by,
among other things, competition and the ability of the Company to
grow and manage growth profitably and retain its key employees; our
ongoing leadership transition; changes in applicable laws or
regulations; the ability of the Company to raise financing in the
future; the success, cost and timing of the Company's product
development and commercialization activities; the commercialization
and adoption of the Company’s existing products and the success of
any product the Company may offer in the future; the potential
attributes and benefits of the Company’s commercialized PlatinumTM
protein sequencing instrument and the Company’s other products once
commercialized; the Company's ability to obtain and maintain
regulatory approval for its products, and any related restrictions
and limitations of any approved product; the Company's ability to
identify, in-license or acquire additional technology; the
Company's ability to maintain its existing lease, license,
manufacture and supply agreements; the Company's ability to compete
with other companies currently marketing or engaged in the
development or commercialization of products and services that
serve customers engaged in proteomic analysis, many of which have
greater financial and marketing resources than the Company; the
size and growth potential of the markets for the Company's products
and services, and its ability to serve those markets once
commercialized, either alone or in partnership with others the
Company's estimates regarding future expenses, future revenue,
capital requirements and needs for additional financing; the
Company's financial performance; and other risks and uncertainties
described under "Risk Factors" in the Company’s Annual Report for
the fiscal year ended December 31, 2022, and in the Company's other
filings with the SEC. The Company cautions that the foregoing list
of factors is not exclusive. The Company cautions readers not to
place undue reliance upon any forward-looking statements, which
speak only as of the date made. The Company does not undertake or
accept any obligation or undertaking to release publicly any
updates or revisions to any forward-looking statements to reflect
any change in its expectations or any change in events, conditions,
or circumstances on which any such statement is based.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231031381818/en/
Investors Jeff Keyes, CFO ir@quantum-si.com
Media Katherine Atkinson, SVP Commercial Marketing
media@quantum-si.com
Quantum Si (NASDAQ:QSI)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Quantum Si (NASDAQ:QSI)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024